[go: up one dir, main page]

US20040175427A1 - Omeprazole formulation - Google Patents

Omeprazole formulation Download PDF

Info

Publication number
US20040175427A1
US20040175427A1 US10/804,255 US80425504A US2004175427A1 US 20040175427 A1 US20040175427 A1 US 20040175427A1 US 80425504 A US80425504 A US 80425504A US 2004175427 A1 US2004175427 A1 US 2004175427A1
Authority
US
United States
Prior art keywords
omeprazole
core
pharmaceutical composition
enteric coating
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/804,255
Inventor
Chih-Ming Chen
Joseph Chou
Unchalee Kositprapa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/143,167 external-priority patent/US6174548B1/en
Application filed by Individual filed Critical Individual
Priority to US10/804,255 priority Critical patent/US20040175427A1/en
Publication of US20040175427A1 publication Critical patent/US20040175427A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Definitions

  • the present invention relates to a stable formulation of omeprazole. It is well known that omeprazole is sensitive to acidic conditions and after contact with an acid, omeprazole will degrade and will not function in its intended manner. Initially, alkaline materials were added to a core of omeprazole and later an enteric coating was applied over the core to prevent the omeprazole from contacting the acidic pH conditions of the stomach. This approach is satisfactory if the product is administered within a short time after it is manufactured but if the product is stored under ambient conditions, the acidic residue of the enteric coating appears to degrade the omeprazole before it is administered to a patient.
  • This dual layer coating technique requires the application of two separate functional coating operations which increases the length of the manufacturing process and the cost of the product.
  • the applicants have surprisingly discovered a coating system which avoids the need to use a coating layer to separate the omeprazole core from the enteric coating layer in an omeprazole dosage form.
  • the separate coating system is based on the combined use of an enteric coating agent which is applied to a pelletized core or a granular core of omeprazole as a suspension in a suitable solvent.
  • the present invention provides a novel stable pharmaceutical composition of omeprazole for oral administration which consists essentially of:
  • the core of the pharmaceutical composition can be in the form of a compressed tablet which is further comprised essentially of a surface active agent, and a binder.
  • the pharmaceutical composition can have a pelleted core which is further comprised essentially of an inert core component, a surface active agent and a binder.
  • omeprazole which is stable upon prolonged storage, is stable when administered to a patient and is capable of providing the desired therapeutic effect.
  • the omeprazole formulation of the invention is preferably based on a core of omeprazole or pharmaceutically equivalent salt, a filler and an alkaline material selected from the group consisting of arginine or lysine; and a single layer of coating on said core which comprises a layer of an enteric coating agent applied from an organic solvent based system.
  • the Omeprazole core can either be pelleted or tabletted as described herein.
  • a filler is used as a granulation substrate.
  • Sugars such as lactose, dextrose, sucrose, maltose, or microcrystalline cellulose and the like may be used as fillers in either the pellet or the granulation composition.
  • the filler may comprise from 20 to 90 wt % and preferably 65-85 wt % based on the total weight of the drug layer composition.
  • the filler may comprise from 20 to 60 wt % and preferably 20 to 40 wt % based on the total weight of the granulation.
  • a tablet disintegrant may be added which comprises corn starch, potato starch, croscarmelose sodium, crospovidone and sodium starch glycolate in an effective amount.
  • An effective amount which may be from 3 to 10 wt % based on the total weight of the granulation.
  • an alkaline agent that is either lysine or arginine is used as a stabilizer.
  • a level of from 20 to 60 wt % and preferably 30 to 55 wt % based on the weight of the granulation may be employed.
  • a level of from 0.5 to 10 wt % and preferably 1 to 3 wt % based on the weight of the pellet may be employed.
  • the enteric coating may comprise an acid resisting material which resists acid up to a pH of above about 5.0 or higher which is selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, Eudragit L (poly(methacrylic acid, methylmethacrylate), 1:1 ratio; MW (No. Av. 135,000—USP Type A) or Eudragit S (poly(methacrylic acid, methylmethacrylate, 1:2 ratio MW (No. Av. 135,000—USP Type B) and mixtures thereof.
  • an acid resisting material which resists acid up to a pH of above about 5.0 or higher which is selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, Eudragit L (poly(methacrylic acid, methylmethacryl
  • the enteric coating agent may also include an inert processing aid in an amount in the case of the tabletted form from 15 to 55 wt % and preferably 20 to 45 wt % based on the total weight of the acid resisting component and the inert processing aid.
  • the inert processing aid is preferably in an amount from 5 to 50 wt % and most preferably 10-20 wt %.
  • the inert processing aids include finely divided forms of talc, silicon dioxide, magnesium stearate etc.
  • Typical solvents which may be used to apply the acid resisting component-inert processing aid mixture include isopropyl alcohol, acetone, methylene chloride and the like.
  • the acid resistant component-inert processing aid mixture will be applied from a 5 to 20 wt % of acid resisting component-inert processing aid mixture based on the total weight of the solvent and the acid resistant component-inert processing aid.
  • omeprazole or a pharmaceutically equivalent salt is used in the core.
  • the omeprazole may comprise from 5 to 70 wt % and preferably 10 to 30 wt % of the granulation.
  • the Omeprazole may comprise from 10 to 50 wt % and preferably 10 to 20 wt % of the drug layer composition.
  • a surface active agent is used in both the tabletted and the pelleted form of the invention.
  • the surface active agent may be any pharmaceutically acceptable, non-toxic surfactant. Suitable surface active agents include sodium lauryl sulfate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 and the like.
  • the surface active agent may be present at a level of from 0.1 to 5 wt %. In the case of the tabletted form the surface active agent is preferably 0.20 to 2.0 wt % based on the total weight of the granulation. In the pelleted form the surface active agent is preferably 0.20 to 2.0 wt % of the total weight of the drug layer composition.
  • the binder is used in both the tabletted and the pelleted form of the invention.
  • the binder may be any pharmaceutically acceptable, non-toxic pharmaceutically acceptable binder.
  • the binder is preferably a water soluble polymer of the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, methylcellulose, hydroxypropyl cellulose, hydroxymethyl cellulose and the like.
  • a water soluble binder is preferred which is applied from an aqueous medium such as water at a level of from 0.1 to 10 wt % and preferably from 0.25 to 7.5 wt % of binder based on the total weight of the granulation.
  • a granulation is formed by contacting the alkaline agent, the omeprazole, the surface active agent and the binder with a medium which may comprise any low viscosity solvent such as water, isopropyl alcohol, acetone, ethanol or the like.
  • a medium which may comprise any low viscosity solvent such as water, isopropyl alcohol, acetone, ethanol or the like.
  • fluids such as water are employed, this will usually require a weight of fluid which is about three times the weight of the dry components of the coating composition.
  • the granulation is tabletted and the tablets are directly coated with the enteric coating agent.
  • a color imparting agent may be added to the enteric coating agent mixture or a rapidly dissolving seal coat containing color may be coated over the enteric coating agent layer provided that the seal coat is compatible with and does not affect the dissolution of the enteric coating layer.
  • the rapidly dissolving seal coat may comprise Opadry pink which comprises approximately 91 wt % hydroxypropyl methylcellulose (E-6), color and 9 wt % polyethylene glycol which is applied as a 8-15% w/w solution in purified water.
  • the color may be provided as Chromateric which is available from Crompton & Knowles.
  • This product contains water, talc, TiO 2 , triethyl citrate, propylene glycol, synthetic red iron oxide, potassium sorbate, xanthan gum, sodium citrate and synthetic yellow iron oxide.
  • conventional sugar based seal coats may be used which contain FDA certified dyes.
  • the invention is preferably based on pellets having a core forming inert component which may comprise a starch or sugar sphere such as non-pareil sugar seeds having an average size of 14 to 35 mesh, preferably about 18 to 20 mesh.
  • the core forming inert component is coated with a formulation which comprises Omeprazole, a surface active agent, a filler, an alkaline material that is either lysine or arginine and a binder, which are collectively referred to as the drug layer composition.
  • the core forming inert component is employed at 1:1 to 5:1 and preferably from 2:1 to 3:1 weight ratio to the drug layer composition.
  • the cores are formed by spraying the non-pareil seeds with an aqueous or non-aqueous suspension which contains the alkaline agent, the omeprazole, the surface active agent and the binder.
  • the suspension medium may comprise any low viscosity solvent such as water, isopropyl alcohol, acetone, ethanol or the like. When fluids such as water are employed , this will usually require a weight of fluid which is about seven times the weight of the dry components of the coating composition.
  • the cores are coated with the enteric coating agent.
  • a color imparting agent may be added to the enteric coating agent mixture or a rapidly dissolving seal coat over the enteric coating agent layer provided that the seal coat is compatible with and does no affect the dissolution of the enteric coating layer.
  • Examples 1 to 5 describe a tabletted form of the invention and Example 6 describes a pelleted form of the invention.
  • a granulation containing omeprazole is formed in a fluid bed coater using a top spray granulation forming suspension containing omeprazole, micronized to 95% less than 15 microns, 5% w/w of the total amount of L-arginine, polyvinyl pyrrolidone, sodium lauryl sulfate and purified water which is sprayed onto a mixture of microcrystalline cellulose, 95% w/w of the total amount of L-arginine and sodium starch glycolate.
  • the formulation for making the granulation has the following composition: povidone, USP (Plasdone K90) 100.0 g sodium starch glycolate 100.0 g sodium lauryl sulfate, NF/USP 6.0 g microcrystalline cellulose (AvicelPH101) 965.6 g L-arginine, USP/FCC 1020.0 g omeprazole, USP (micronized) 340.0 g purified water, USP 1100.0 g
  • omeprazole granules 118.0 g glyceryl monostearate (Myvaplex) 6.0 g Tabletting tools: 0.2812′′ target weight: 124 mg/tab target hardness: 7 Kp LOD of granules: less than 3%
  • enteric coated tablets as follows: omeprazole tablets 124.0 g (prepared above) hydroxypropyl methylcellulose 14.7 g phthalate talc 4.2 g acetyl tributyl citrate 2.9 g acetone 148.0 g isopropyl alcohol 148.0 g
  • a seal coat was applied to the enteric coated tablets as follows: Enteric coated tablet 146.0 g Opadry II pink 4.5 g Water 450.0 g
  • seal coat was applied onto the enteric coated omeprazole tablets using a perforated pan coater.
  • a granulation containing omeprazole is formed in fluid bed coater using a top spray granulation forming suspension containing omeprazole, micronized to 95% less than 15 microns, 2.68% w/w of the total amount of L-arginine, polyvinyl pyrrolidone, polysorbate 80 and purified water which is sprayed onto a mixture of microcrystalline cellulose and 95.0% w/w of the total amount of L-arginine.
  • the formulation for making the granulation has the following composition: mg/ tablet povidone, USP (Plasdone K90) 5.88 polysorbate 80 (Tween 80) 0.58 L-arginine, USP/FCC 60.0 omeprazole, USP (micronized) 20.0 microcrystalline cellulose (Avicel PH102) 25.54 purified water, USP n/a
  • omeprazole granules 112.0 mg glyceryl monostearate (Myvaplex) 6.8 mg crospovidone XL 16.2 mg Tabletting tools: 0.2812′′ target weight: 135 mg/tab target hardness: 7 Kp LOD of granules: less than 3%
  • enteric coated tablets were prepared as follows: omeprazole tablets 135.0 mg (prepared above) Eudragit L30D-55 14.0 mg color (Chromateric) 7.0 mg 1M NaOH (to adjust pH to 5.0)qs na Purified water qs na
  • a granulation containing omeprazole is formed in fluid bed coater using a top spray granulation forming suspension containing omeprazole, micronized to 95% less than 15 microns, 5.0% w/w of the total amount of L-arginine, polyvinyl pyrrolidone, sodium lauryl sulfate and purified water which is sprayed onto a mixture of microcrystalline cellulose and 95.0% w/w of the total amount of L-arginine.
  • the formulation for making the granulation has the following composition: mg/tablet povidone, USP (Plasdone K90) 5.0 sodium lauryl sulfate 0.3 L-arginine, USP/FCC 60.0 omeprazole, USP (micronized) 10.0 g microcrystalline cellulose (AvicelPH102) 24.7 purified water, USP n/a
  • omeprazole granules 100.0 mg glyceryl monostearate (Myvaplex) 5.0 mg sodium starch glycolate 5.0 mg Tabletting tools: 0.2812′′ target weight: 110 mg/tab target hardness: 7 Kp LOD of granules: less than 3%
  • a granulation containing omeprazole is formed in fluid bed coater using a top spray granulation forming suspension containing omeprazole, micronized to 95% less than 15 microns, 5.0% w/w of the total amount of L-arginine, polyvinyl pyrrolidone, sodium lauryl sulfate and purified water which is sprayed onto a mixture of microcrystalline cellulose and 95.0% w/w of the total amount of L-arginine.
  • the formulation for making the granulation has the following composition: mg/tablet povidone, USP (Plasdone K90) 5.88 polysorbate 80 0.60 L-arginine, USP/FCC 60.0 omeprazole, USP (micronized) 20.0 crospovidone XL 5.88 microcrystalline cellulose 25.54 purified water, USP n/a
  • the granulation is tabletted into tablets containing 20 mg of omeprazole by first mixing the omeprazole granules with glyceryl monostearate: omeprazole granules 117.9 mg glyceryl monostearate (Myvaplex) 6.1 mg Tabletting tools: 0.2812′′ target weight: 124 mg/tab target hardness: 7 Kp LOD of granules: less than 3%
  • Example 1 The granulation of Example 1 was prepared and tabletted into tablets containing 20.0 mg of omeprazole. These tablets were coated as follows:
  • enteric coated tablets were prepared as follows: omeprazole tablets 126.00 mg (prepared above) Eudragit L30D-55 17.00 mg 1M NaOH (to adjust pH to 5.0) qs na acetyl tributyl citrate 1.70 mg talc 3.80 mg polysorbate 80 1.50 mg Purified water qs na
  • the core is comprised of omeprazole, a surface active agent, a filler, an alkaline material and a binder.
  • Omeprazole activated pellets (sodium free) are prepared as follows: 13.650 kg of Purified water is dispensed into a suitably sized stainless steel container. L-Arginine Base (0.210 kg), Lactose Anhydrous, NF (1.75 kg) and Povidone (Plasdone ®K-90) (0.056 kg) is added to the purified water while homogenizing at full speed (about 5,000 rpm). Homogenizing is continued until the materials are completely dissolved. Polysorbate 80, NF (0.044 kg) is added to the solution while homogenizing at a lower speed (700-3300 rpm) to avoid excess foaming.
  • the material is homogenized until dissolved completely.
  • Half of the solution (7.855 kg) is transferred into a 5-10 gallon stainless steel container.
  • the original container is hereafter referred to as “container A” and the new container is henceforth referred to as “container B.”
  • Micronized omeprazole 95% less than 15 microns (0.980 kg) is added to container A while homogenizing at a lower speed (700-3300 rpm) to avoid excess foaming.
  • the Omeprazole is allowed to disperse into the solution completely and then homogenized for another 10 minutes.
  • the homogenizer is replaced with a mechanical stirrer and the suspension is continuously stirred throughout the coating process.
  • omeprazole suspension in container A When approximately three fourth of the omeprazole suspension in container A is consumed, 0.980 kg of micronized omeprazole is added to container B while homogenizing at a lower speed (700-3300) to avoid excess foaming.
  • the Omeprazole is allowed to disperse in the solution completely and homogenization is continued for another 10 minutes.
  • the homogenizer is replaced with a mechanical stirrer and the suspension is continuously stirred throughout the coating process.
  • 9.98 kg of sugar spheres are added to a fluidized bed coater and preheated until the product reaches 40-45° C.
  • the drug suspension from containers A and B are sprayed onto the spheres.
  • the atomization pressure is between 1.5 to 3.5 bar and the; pump rate is 2-100 ml/min.
  • the spray rate does not exceed 20 ml/min in the first two hours to avoid agglomeration of the sugar spheres.
  • the coating suspension is transferred to a smaller container to facilitate stirring when the surface of the coating suspension reaches the stirring blade. After the coating suspension has been consumed the pump is stopped and the fluidization is continued in the fluidized bed coater with the heat off until the product temperature drops below 32° C.
  • the pellets are then transferred to a fluidized bed coater into a 50° C. oven (45-55° C.). The pellets are dried until the moisture content of the pellets is not more then 2.5%. The pellets are separated into different size fractions by using a SWECO Separator equipped with 14 and 24 mesh screens. The pellets are collected in doubled polyethylene lined plastic containers and stored with desiccant.
  • Talc (1.683 kg) is added while stirring. The talc is mixed until fully dispersed in the solution and the mixing is continued throughout the entire coating process. A fluidized bed coater is preheated to 32° C. The omeprazole active pellets (11.550 kg) are loaded into the fluidized bed coater and preheated until the temperature reaches 30° C.
  • the coating suspension is sprayed on the pellets using a product temperature of 25-35° C., an atomization pressure of 1.5 to 3.0 bar and a pump rate of 200-300 ml/min.
  • the coating suspension is transferred to a smaller container to facilitate stirring when the surface of the coating suspension reaches the stirring blade.
  • the coated pellets are dried in a fluidized bed coater for 20 minutes using the same coating conditions except lowering the atomization pressure to 2 bars or below.
  • the coated pellets are discharged into double polyethylene bags.
  • the pellets are separated into different size fractions by using a SWECO separator equipped with 14 and 24 mesh screens. The pellets which are larger than 14 mesh and smaller than 24 mesh are rejected.
  • the pellets that passed through the 14 mesh and retained on the 24 mesh are retained in polyethylene bags.
  • Omeprazole enteric coated pellets (Sodium Free), blended are prepared as follows:
  • An encapsulation room is prepared in which the relative humidity is in the range of 35-65% and the temperature is in the range of 15-25° C.
  • Omeprazole enteric coated pellets (Sodium Free) blended are encapsulated using the following equipment and guidelines.
  • a capsule machine model MACOFAR MT-20 is prepared for the procedure placing the machine setting at 4, using capsule machine size part 1, capsule magazine 1.
  • the target filled capsule weight is 457.15 mg. If the total weight is not within 3% of the target weight, further adjustment must be performed.
  • Capsule fill verification is performed at twenty minutes intervals on ten individual capsules. Acceptable capsules are collected in containers lined with double polyethylene bags and placed under desiccant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A stable pharmaceutical composition of omeprazole for oral administration which consists essentially of: (a) a core of Omeprazole or a pharmaceutically equivalent salt, a filler and an alkaline material selected from the group consisting of lysing and arginine; and (b) a single layer of coating on said core which comprises a layer of an enteric coating agent which is applied from an organic solvent based system.

Description

    BACKGROUND OF THE INVENTION
  • The present invention relates to a stable formulation of omeprazole. It is well known that omeprazole is sensitive to acidic conditions and after contact with an acid, omeprazole will degrade and will not function in its intended manner. Initially, alkaline materials were added to a core of omeprazole and later an enteric coating was applied over the core to prevent the omeprazole from contacting the acidic pH conditions of the stomach. This approach is satisfactory if the product is administered within a short time after it is manufactured but if the product is stored under ambient conditions, the acidic residue of the enteric coating appears to degrade the omeprazole before it is administered to a patient. To solve this problem, the prior art has used a separate layer of a coating agent to coat a pellet core which contains omeprazole and an alkaline material which is thereafter coated with the enteric coating. This technique is described in U.S. Pat. No. 4,786,505. In addition WO 96/24338 discloses the use of an in situ formed interlayer that is based on the reaction of an aqueous enteric coating material with an alkaline material in the core. [0001]
  • This dual layer coating technique requires the application of two separate functional coating operations which increases the length of the manufacturing process and the cost of the product. The applicants have surprisingly discovered a coating system which avoids the need to use a coating layer to separate the omeprazole core from the enteric coating layer in an omeprazole dosage form. The separate coating system is based on the combined use of an enteric coating agent which is applied to a pelletized core or a granular core of omeprazole as a suspension in a suitable solvent. [0002]
  • The applicants have also surprisingly discovered that arginine or lysine can be used as a pH stabilizing agent. [0003]
    • SUMMARY OF THE INVENTION
  • The present invention provides a novel stable pharmaceutical composition of omeprazole for oral administration which consists essentially of: [0004]
  • (a) a core of omeprazole or a pharmaceutically equivalent salt, a filler and an alkaline material selected from the group consisting of lysine and arginine; and [0005]
  • (b) a single layer of coating on said core which comprises a layer of an enteric coating agent applied from an organic based solvent coating system. [0006]
  • The core of the pharmaceutical composition can be in the form of a compressed tablet which is further comprised essentially of a surface active agent, and a binder. Alternatively, the pharmaceutical composition can have a pelleted core which is further comprised essentially of an inert core component, a surface active agent and a binder. [0007]
  • Accordingly, it is a primary object of this invention to provide a pharmaceutical dosage formulation of omeprazole which is stable upon prolonged storage, is stable when administered to a patient and is capable of providing the desired therapeutic effect. [0008]
  • It is also an object of this invention to provide a pharmaceutical dosage form of omeprazole which is bioequivalent to dosage forms of omeprazole which have an intermediate layer of an inert coating material. [0009]
  • It is also an object of this invention to provide a stable dosage form of omeprazole which may be produced without the need to provide an intermediate coating layer that separates the omeprazole containing core from the enteric coating layer. [0010]
  • These and other objects of the invention will become apparent from a review of the appended specification.[0011]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The omeprazole formulation of the invention is preferably based on a core of omeprazole or pharmaceutically equivalent salt, a filler and an alkaline material selected from the group consisting of arginine or lysine; and a single layer of coating on said core which comprises a layer of an enteric coating agent applied from an organic solvent based system. The Omeprazole core can either be pelleted or tabletted as described herein. [0012]
  • In the case of both the pelleted form and the tabletted form of the core a filler is used. A filler is used as a granulation substrate. Sugars such as lactose, dextrose, sucrose, maltose, or microcrystalline cellulose and the like may be used as fillers in either the pellet or the granulation composition. In the case of the pelleted form the filler may comprise from 20 to 90 wt % and preferably 65-85 wt % based on the total weight of the drug layer composition. In the case of the tabletted form the filler may comprise from 20 to 60 wt % and preferably 20 to 40 wt % based on the total weight of the granulation. In the case of the tabletted form of the invention a tablet disintegrant may be added which comprises corn starch, potato starch, croscarmelose sodium, crospovidone and sodium starch glycolate in an effective amount. An effective amount which may be from 3 to 10 wt % based on the total weight of the granulation. [0013]
  • In the case of both the tabletted form and the pelleted form of the core an alkaline agent that is either lysine or arginine is used as a stabilizer. In the case of the tabletted form a level of from 20 to 60 wt % and preferably 30 to 55 wt % based on the weight of the granulation may be employed. In the case of the pelleted form a level of from 0.5 to 10 wt % and preferably 1 to 3 wt % based on the weight of the pellet may be employed. [0014]
  • In the case of both the pelleted form and the tabletted form of the invention an enteric coating agent is placed over the core. In both cases the enteric coating may comprise an acid resisting material which resists acid up to a pH of above about 5.0 or higher which is selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, Eudragit L (poly(methacrylic acid, methylmethacrylate), 1:1 ratio; MW (No. Av. 135,000—USP Type A) or Eudragit S (poly(methacrylic acid, methylmethacrylate, 1:2 ratio MW (No. Av. 135,000—USP Type B) and mixtures thereof. [0015]
  • The enteric coating agent may also include an inert processing aid in an amount in the case of the tabletted form from 15 to 55 wt % and preferably 20 to 45 wt % based on the total weight of the acid resisting component and the inert processing aid. In the case of the pelleted form the inert processing aid is preferably in an amount from 5 to 50 wt % and most preferably 10-20 wt %. The inert processing aids include finely divided forms of talc, silicon dioxide, magnesium stearate etc. Typical solvents which may be used to apply the acid resisting component-inert processing aid mixture include isopropyl alcohol, acetone, methylene chloride and the like. Generally the acid resistant component-inert processing aid mixture will be applied from a 5 to 20 wt % of acid resisting component-inert processing aid mixture based on the total weight of the solvent and the acid resistant component-inert processing aid. [0016]
  • In the case of both the tabletted form and the pelleted form of the invention omeprazole or a pharmaceutically equivalent salt is used in the core. in the tabletted formulation the omeprazole may comprise from 5 to 70 wt % and preferably 10 to 30 wt % of the granulation. In the pelleted form the Omeprazole may comprise from 10 to 50 wt % and preferably 10 to 20 wt % of the drug layer composition. [0017]
  • A surface active agent is used in both the tabletted and the pelleted form of the invention. The surface active agent may be any pharmaceutically acceptable, non-toxic surfactant. Suitable surface active agents include sodium lauryl sulfate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 and the like. The surface active agent may be present at a level of from 0.1 to 5 wt %. In the case of the tabletted form the surface active agent is preferably 0.20 to 2.0 wt % based on the total weight of the granulation. In the pelleted form the surface active agent is preferably 0.20 to 2.0 wt % of the total weight of the drug layer composition. [0018]
  • The binder is used in both the tabletted and the pelleted form of the invention. The binder may be any pharmaceutically acceptable, non-toxic pharmaceutically acceptable binder. The binder is preferably a water soluble polymer of the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, methylcellulose, hydroxypropyl cellulose, hydroxymethyl cellulose and the like. A water soluble binder is preferred which is applied from an aqueous medium such as water at a level of from 0.1 to 10 wt % and preferably from 0.25 to 7.5 wt % of binder based on the total weight of the granulation. [0019]
  • In the case of the tabletted form of the invention a granulation is formed by contacting the alkaline agent, the omeprazole, the surface active agent and the binder with a medium which may comprise any low viscosity solvent such as water, isopropyl alcohol, acetone, ethanol or the like. When fluids such as water are employed, this will usually require a weight of fluid which is about three times the weight of the dry components of the coating composition. [0020]
  • After the granulation is formed and dried, the granulation is tabletted and the tablets are directly coated with the enteric coating agent. A color imparting agent may be added to the enteric coating agent mixture or a rapidly dissolving seal coat containing color may be coated over the enteric coating agent layer provided that the seal coat is compatible with and does not affect the dissolution of the enteric coating layer. The rapidly dissolving seal coat may comprise Opadry pink which comprises approximately 91 wt % hydroxypropyl methylcellulose (E-6), color and 9 wt % polyethylene glycol which is applied as a 8-15% w/w solution in purified water. In addition the color may be provided as Chromateric which is available from Crompton & Knowles. This product contains water, talc, TiO[0021] 2, triethyl citrate, propylene glycol, synthetic red iron oxide, potassium sorbate, xanthan gum, sodium citrate and synthetic yellow iron oxide. If desired, conventional sugar based seal coats may be used which contain FDA certified dyes.
  • In the case of a pelleted form the invention is preferably based on pellets having a core forming inert component which may comprise a starch or sugar sphere such as non-pareil sugar seeds having an average size of 14 to 35 mesh, preferably about 18 to 20 mesh. The core forming inert component is coated with a formulation which comprises Omeprazole, a surface active agent, a filler, an alkaline material that is either lysine or arginine and a binder, which are collectively referred to as the drug layer composition. The core forming inert component is employed at 1:1 to 5:1 and preferably from 2:1 to 3:1 weight ratio to the drug layer composition. [0022]
  • The cores are formed by spraying the non-pareil seeds with an aqueous or non-aqueous suspension which contains the alkaline agent, the omeprazole, the surface active agent and the binder. The suspension medium may comprise any low viscosity solvent such as water, isopropyl alcohol, acetone, ethanol or the like. When fluids such as water are employed , this will usually require a weight of fluid which is about seven times the weight of the dry components of the coating composition. [0023]
  • After the cores are dried, the cores are coated with the enteric coating agent. A color imparting agent may be added to the enteric coating agent mixture or a rapidly dissolving seal coat over the enteric coating agent layer provided that the seal coat is compatible with and does no affect the dissolution of the enteric coating layer. [0024]
    • DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • Examples 1 to 5 describe a tabletted form of the invention and Example 6 describes a pelleted form of the invention. [0025]
    • EXAMPLE 1
  • Granulation. [0026]
  • A granulation containing omeprazole is formed in a fluid bed coater using a top spray granulation forming suspension containing omeprazole, micronized to 95% less than 15 microns, 5% w/w of the total amount of L-arginine, polyvinyl pyrrolidone, sodium lauryl sulfate and purified water which is sprayed onto a mixture of microcrystalline cellulose, 95% w/w of the total amount of L-arginine and sodium starch glycolate. The formulation for making the granulation has the following composition: [0027]
    povidone, USP (Plasdone K90) 100.0 g
    sodium starch glycolate 100.0 g
    sodium lauryl sulfate, NF/USP 6.0 g
    microcrystalline cellulose (AvicelPH101) 965.6 g
    L-arginine, USP/FCC 1020.0 g
    omeprazole, USP (micronized) 340.0 g
    purified water, USP 1100.0 g
  • Tabletting. [0028]
  • The granulation is tabletted into tablets containing 20 mg of omeprazole by first mixing the omeprazole granules with glyceryl monostearate: [0029]
    omeprazole granules 118.0 g
    glyceryl monostearate (Myvaplex) 6.0 g
    Tabletting tools: 0.2812″
    target weight: 124 mg/tab
    target hardness: 7 Kp
    LOD of granules: less than 3%
  • Enteric Coating. [0030]
  • An enteric coating is applied to prepare enteric coated tablets as follows: [0031]
    omeprazole tablets 124.0 g
    (prepared above)
    hydroxypropyl methylcellulose 14.7 g
    phthalate
    talc 4.2 g
    acetyl tributyl citrate 2.9 g
    acetone 148.0 g
    isopropyl alcohol 148.0 g
  • The solid coating materials were dissolved in the acetone and isopropyl alcohol and this solution was coated onto the omeprazole tablets using a perforated pan [0032]
  • Seal Coat: [0033]
  • A seal coat was applied to the enteric coated tablets as follows: [0034]
    Enteric coated tablet 146.0 g
    Opadry II pink 4.5 g
    Water 450.0 g
  • The seal coat was applied onto the enteric coated omeprazole tablets using a perforated pan coater. [0035]
    • EXAMPLE 2
  • Granulation. [0036]
  • A granulation containing omeprazole is formed in fluid bed coater using a top spray granulation forming suspension containing omeprazole, micronized to 95% less than 15 microns, 2.68% w/w of the total amount of L-arginine, polyvinyl pyrrolidone, polysorbate 80 and purified water which is sprayed onto a mixture of microcrystalline cellulose and 95.0% w/w of the total amount of L-arginine. The formulation for making the granulation has the following composition: [0037]
    mg/ tablet
    povidone, USP (Plasdone K90) 5.88
    polysorbate 80 (Tween 80) 0.58
    L-arginine, USP/FCC 60.0
    omeprazole, USP (micronized) 20.0
    microcrystalline cellulose (Avicel PH102) 25.54
    purified water, USP n/a
  • Tabletting. [0038]
  • The granulation is tabletted into tablets containing 20 mg of omeprazole by first mixing the omeprazole granules with glyceryl monostearate: [0039]
    omeprazole granules 112.0 mg
    glyceryl monostearate (Myvaplex) 6.8 mg
    crospovidone XL 16.2 mg
    Tabletting tools: 0.2812″
    target weight: 135 mg/tab
    target hardness: 7 Kp
    LOD of granules: less than 3%
  • Enteric Coating. [0040]
  • An enteric coating was applied to prepare enteric coated tablets as follows: [0041]
    omeprazole tablets 135.0 mg
    (prepared above)
    Eudragit L30D-55 14.0 mg
    color (Chromateric) 7.0 mg
    1M NaOH (to adjust pH to 5.0)qs na
    Purified water qs na
  • The solid coating materials were dispersed in the water and this mixture was coated onto the omeprazole tablets using a perforated pan. [0042]
    • EXAMPLE 3
  • Granulation. [0043]
  • A granulation containing omeprazole is formed in fluid bed coater using a top spray granulation forming suspension containing omeprazole, micronized to 95% less than 15 microns, 5.0% w/w of the total amount of L-arginine, polyvinyl pyrrolidone, sodium lauryl sulfate and purified water which is sprayed onto a mixture of microcrystalline cellulose and 95.0% w/w of the total amount of L-arginine. The formulation for making the granulation has the following composition: [0044]
    mg/tablet
    povidone, USP (Plasdone K90) 5.0
    sodium lauryl sulfate 0.3
    L-arginine, USP/FCC 60.0
    omeprazole, USP (micronized) 10.0 g
    microcrystalline cellulose (AvicelPH102) 24.7
    purified water, USP n/a
  • Tabletting. [0045]
  • The granulation is tabletted into tablets containing 10 mg of omeprazole by first mixing the omeprazole granules with glyceryl monostearate: [0046]
    omeprazole granules 100.0 mg
    glyceryl monostearate (Myvaplex) 5.0 mg
    sodium starch glycolate 5.0 mg
    Tabletting tools: 0.2812″
    target weight: 110 mg/tab
    target hardness: 7 Kp
    LOD of granules: less than 3%
  • Enteric Coating. [0047]
  • The tablets were coated with the same enteric coating that was applied to the tablets in Example 2. [0048]
    • EXAMPLE 4
  • Granulation. [0049]
  • A granulation containing omeprazole is formed in fluid bed coater using a top spray granulation forming suspension containing omeprazole, micronized to 95% less than 15 microns, 5.0% w/w of the total amount of L-arginine, polyvinyl pyrrolidone, sodium lauryl sulfate and purified water which is sprayed onto a mixture of microcrystalline cellulose and 95.0% w/w of the total amount of L-arginine. The formulation for making the granulation has the following composition: [0050]
    mg/tablet
    povidone, USP (Plasdone K90) 5.88
    polysorbate 80 0.60
    L-arginine, USP/FCC 60.0
    omeprazole, USP (micronized) 20.0
    crospovidone XL 5.88
    microcrystalline cellulose 25.54
    purified water, USP n/a
  • Tabletting. [0051]
  • The granulation is tabletted into tablets containing 20 mg of omeprazole by first mixing the omeprazole granules with glyceryl monostearate: [0052]
    omeprazole granules 117.9 mg
    glyceryl monostearate (Myvaplex)  6.1 mg
    Tabletting tools: 0.2812″
    target weight: 124 mg/tab
    target hardness: 7 Kp
    LOD of granules: less than 3%
  • Enteric Coating. [0053]
  • The tablets were coated with the same enteric coating that was applied to the tablets in Example 1. [0054]
    • EXAMPLE 5
  • The granulation of Example 1 was prepared and tabletted into tablets containing 20.0 mg of omeprazole. These tablets were coated as follows: [0055]
  • Enteric coating. [0056]
  • An enteric coating was applied to prepare enteric coated tablets as follows: [0057]
    omeprazole tablets 126.00 mg
    (prepared above)
    Eudragit L30D-55  17.00 mg
    1M NaOH (to adjust pH to 5.0) qs na
    acetyl tributyl citrate  1.70 mg
    talc  3.80 mg
    polysorbate 80  1.50 mg
    Purified water qs na
  • The solid coating materials were dispersed in the water and this mixture was coated onto the omeprazole tablets using a perforated pan. A seal coat was applied using the procedure of Example 1. [0058]
    • EXAMPLE 6
  • In the case of a pharmaceutical formulation with a pelleted omeprazole core, the core is comprised of omeprazole, a surface active agent, a filler, an alkaline material and a binder. [0059]
  • Omeprazole activated pellets (sodium free) are prepared as follows: 13.650 kg of Purified water is dispensed into a suitably sized stainless steel container. L-Arginine Base (0.210 kg), Lactose Anhydrous, NF (1.75 kg) and Povidone (Plasdone ®K-90) (0.056 kg) is added to the purified water while homogenizing at full speed (about 5,000 rpm). Homogenizing is continued until the materials are completely dissolved. Polysorbate 80, NF (0.044 kg) is added to the solution while homogenizing at a lower speed (700-3300 rpm) to avoid excess foaming. [0060]
  • The material is homogenized until dissolved completely. Half of the solution (7.855 kg) is transferred into a 5-10 gallon stainless steel container. The original container is hereafter referred to as “container A” and the new container is henceforth referred to as “container B.” Micronized omeprazole 95% less than 15 microns (0.980 kg) is added to container A while homogenizing at a lower speed (700-3300 rpm) to avoid excess foaming. The Omeprazole is allowed to disperse into the solution completely and then homogenized for another 10 minutes. The homogenizer is replaced with a mechanical stirrer and the suspension is continuously stirred throughout the coating process. When approximately three fourth of the omeprazole suspension in container A is consumed, 0.980 kg of micronized omeprazole is added to container B while homogenizing at a lower speed (700-3300) to avoid excess foaming. The Omeprazole is allowed to disperse in the solution completely and homogenization is continued for another 10 minutes. The homogenizer is replaced with a mechanical stirrer and the suspension is continuously stirred throughout the coating process. 9.98 kg of sugar spheres are added to a fluidized bed coater and preheated until the product reaches 40-45° C. The drug suspension from containers A and B are sprayed onto the spheres. The atomization pressure is between 1.5 to 3.5 bar and the; pump rate is 2-100 ml/min. The spray rate does not exceed 20 ml/min in the first two hours to avoid agglomeration of the sugar spheres. The coating suspension is transferred to a smaller container to facilitate stirring when the surface of the coating suspension reaches the stirring blade. After the coating suspension has been consumed the pump is stopped and the fluidization is continued in the fluidized bed coater with the heat off until the product temperature drops below 32° C. [0061]
  • The pellets are then transferred to a fluidized bed coater into a 50° C. oven (45-55° C.). The pellets are dried until the moisture content of the pellets is not more then 2.5%. The pellets are separated into different size fractions by using a SWECO Separator equipped with 14 and 24 mesh screens. The pellets are collected in doubled polyethylene lined plastic containers and stored with desiccant. [0062]
  • Enteric Coating Process [0063]
  • 10.844 kg of isopropyl alcohol, USP is dispensed into a suitably sized stainless steel container. 10.844 kg of acetone is added to the isopropyl alcohol. 1.683 kg of hydroxypropyl methylcellulose phthalate (Hypromellose 55, Substitution type 200731) and cetyl alcohol, NF (0.084 kg) are added to the solution while homogenizing at full speed until all the materials are dissolved completely. The homegnizer is then removed and replaced with a mechanical stirrer. [0064]
  • Talc (1.683 kg) is added while stirring. The talc is mixed until fully dispersed in the solution and the mixing is continued throughout the entire coating process. A fluidized bed coater is preheated to 32° C. The omeprazole active pellets (11.550 kg) are loaded into the fluidized bed coater and preheated until the temperature reaches 30° C. [0065]
  • The coating suspension is sprayed on the pellets using a product temperature of 25-35° C., an atomization pressure of 1.5 to 3.0 bar and a pump rate of 200-300 ml/min. The coating suspension is transferred to a smaller container to facilitate stirring when the surface of the coating suspension reaches the stirring blade. [0066]
  • After the coating suspension has been consumed the coated pellets are dried in a fluidized bed coater for 20 minutes using the same coating conditions except lowering the atomization pressure to 2 bars or below. The coated pellets are discharged into double polyethylene bags. The pellets are separated into different size fractions by using a SWECO separator equipped with 14 and 24 mesh screens. The pellets which are larger than 14 mesh and smaller than 24 mesh are rejected. The pellets that passed through the 14 mesh and retained on the 24 mesh are retained in polyethylene bags. [0067]
  • Blending [0068]
  • Omeprazole enteric coated pellets (Sodium Free), blended are prepared as follows: [0069]
  • 14.400 kg of omeprazole enteric coated pellets (Sodium free) are charged into a blender. Talc, USP (0.225 kg) is sprinkled on top of the pellet bed and then blended at 28 rpm for 5 minutes. 0.2 to 0.5 grams of each sample is withdrawn into separate vials from the blender. The blended pellets are unloaded into plastic containers lined with double polyethylene. The excess talc is screened off using a SWECO separator equipped with a 24 mesh screen. The pellets are collected in containers lined with double polyethylene bags and stored with desiccant. [0070]
  • Encapsulation [0071]
  • An encapsulation room is prepared in which the relative humidity is in the range of 35-65% and the temperature is in the range of 15-25° C. Omeprazole enteric coated pellets (Sodium Free) blended are encapsulated using the following equipment and guidelines. A capsule machine model MACOFAR MT-20 is prepared for the procedure placing the machine setting at 4, using capsule machine size part 1, capsule magazine 1. The target filled capsule weight is 457.15 mg. If the total weight is not within 3% of the target weight, further adjustment must be performed. Capsule fill verification is performed at twenty minutes intervals on ten individual capsules. Acceptable capsules are collected in containers lined with double polyethylene bags and placed under desiccant. [0072]
  • While certain preferred and alternative embodiments of the invention have been set forth for purposes of disclosing the invention, modifications to the disclosed embodiments may occur to those who are skilled in the art. Accordingly, the appended claims are intended to cover all embodiments of the invention and modifications thereof which do not depart from the spirit and scope of the invention. [0073]

Claims (11)

1. A stable pharmaceutical composition of omeprazole for oral administration which consists essentially of:
(a) a core of Omeprazole or a pharmaceutically equivalent salt, a filler and an alkaline material selected from the group consisting of lysine and arginine; and
(b) a single layer of coating on said core which comprises a layer of an enteric coating agent applied from an organic solvent based system.
2. A pharmaceutical composition of omeprazole as defined in claim 1 wherein said core is further comprised essentially of a surface active agent, and a binder and said pharmaceutical composition is formed into a compressed tablet.
3. A pharmaceutical composition as defined in claim 1 wherein said core is further comprised essentially of a an inert core component, a surface active agent and a binder and said pharmaceutical composition is pelleted.
4. A pharmaceutical composition of omeprazole as defined in claim 2 wherein the acid resistant component is selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters.
5. A pharmaceutical composition of omeprazole as defined in claim 3 wherein the acid resistant component is selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters.
6. A pharmaceutical composition of omeprazole as defined in claim 1 wherein the enteric coating agent also includes an inert processing aid.
7. A pharmaceutical composition of omeprazole as defined in claim 1 wherein the enteric coating agent around the core includes from 5 to 55wt % by weight of the coating of an inert processing aid.
8. A pharmaceutical composition of omeprazole as defined in claim 1 which includes a sodium lauryl sulfate as the surface active agent.
9. A pharmaceutical dosage formulation which consists essentially of:
(a) a tablet core comprising omeprazole, a binder, an alkaline agent selected from the group consisting of arginine or lysine, a filler; and
(b) an enteric coating agent around said core, said enteric coating comprising hydroxypropylmethyl cellulose phthalate and talc.
10. A pharmaceutical composition as defined in claim 3
wherein the core contains a non-pariel sugar seed.
11. A pelleted pharmaceutical dosage formulation which consists essentially of:
(a) a core comprising a non-pariel sugar seed coated with drug layer composition comprising omeprazole, a binder, an alkaline agent selected from the list consisting of arginine and -lysine, a filler and a surface active agent; and
(b) an enteric coating agent around said core, said enteric coating comprising hydroxypropylmethyl cellulose phthalate and talc which is applied from an organic solvent based system.
US10/804,255 1998-08-28 2004-03-19 Omeprazole formulation Abandoned US20040175427A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/804,255 US20040175427A1 (en) 1998-08-28 2004-03-19 Omeprazole formulation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/143,167 US6174548B1 (en) 1998-08-28 1998-08-28 Omeprazole formulation
US09/763,831 US6733778B1 (en) 1999-08-27 1999-08-27 Omeprazole formulation
US10/804,255 US20040175427A1 (en) 1998-08-28 2004-03-19 Omeprazole formulation

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US09/763,831 Continuation US6733778B1 (en) 1998-08-28 1999-08-27 Omeprazole formulation
PCT/US1999/019847 Continuation WO2000012064A1 (en) 1998-08-28 1999-08-27 Omeprazole formulation

Publications (1)

Publication Number Publication Date
US20040175427A1 true US20040175427A1 (en) 2004-09-09

Family

ID=32230706

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/763,831 Expired - Fee Related US6733778B1 (en) 1998-08-28 1999-08-27 Omeprazole formulation
US10/712,505 Expired - Fee Related US6855336B2 (en) 1998-08-28 2003-11-13 Omeprazole formulation
US10/804,255 Abandoned US20040175427A1 (en) 1998-08-28 2004-03-19 Omeprazole formulation

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/763,831 Expired - Fee Related US6733778B1 (en) 1998-08-28 1999-08-27 Omeprazole formulation
US10/712,505 Expired - Fee Related US6855336B2 (en) 1998-08-28 2003-11-13 Omeprazole formulation

Country Status (1)

Country Link
US (3) US6733778B1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196485A1 (en) * 1999-06-22 2007-08-23 Dexcel Ltd. Stable benzimidazole formulation
US20070243243A1 (en) * 2006-04-04 2007-10-18 Cogentus Pharmaceuticals, Inc Oral dosage forms including an antiplatelet agent and an acid inhibitor
US20090214602A1 (en) * 2006-04-04 2009-08-27 Mark Goldsmith Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
US20110038933A1 (en) * 2008-05-06 2011-02-17 Dexcell Ltd. Stable benzimidazole formulation
US10137111B2 (en) 2016-08-11 2018-11-27 Adamis Pharmaceuticals Corporation Drug compositions comprising an anti-parasitic and proton pump inhibitor
US10835488B2 (en) 2016-06-16 2020-11-17 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11564910B2 (en) 2017-12-08 2023-01-31 Adamis Pharmaceuticals Corporation Drug compositions

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
IT1319655B1 (en) 2000-11-15 2003-10-23 Eurand Int PANCREATIC ENZYME MICROSPHERES WITH HIGH STABILITY AND RELATIVE PREPARATION METHOD.
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US20090117180A1 (en) * 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
TWI421090B (en) 2007-02-20 2014-01-01 Aptalis Pharma Ltd Stable digestive enzyme compositions
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
PT2621476E (en) 2010-10-01 2014-10-16 Aptalis Pharma Ltd Enteric coated, low-strength pancrelipase formulations
RU2016119726A (en) 2011-08-08 2018-11-02 Апталис Фарма Лтд. The method of conducting a test for the dissolution of solid compositions containing digestive enzymes
WO2015020943A2 (en) 2013-08-09 2015-02-12 Aptalis Pharma Ltd. Digestive enzyme composition suitable for enteral administration
JP2017519490A (en) 2014-06-19 2017-07-20 アプタリス ファルマ リミテッド Methods for removing viral contamination from pancreatic extracts
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN112957340B (en) * 2021-02-09 2022-03-04 桂林华信制药有限公司 Omeprazole enteric capsule and preparation method thereof
CN118649151B (en) * 2024-06-28 2025-06-24 海南恒诚三叶制药有限公司 Omeprazole enteric capsule and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786505A (en) * 1986-04-30 1988-11-22 Aktiebolaget Hassle Pharmaceutical preparation for oral use
US5219870A (en) * 1990-02-27 1993-06-15 Kwang Sik Kim Omeprazole compositions designed for administration in rectum
US6013281A (en) * 1995-02-09 2000-01-11 Astra Aktiebolag Method of making a pharmaceutical dosage form comprising a proton pump inhibitor
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6602522B1 (en) * 1997-11-14 2003-08-05 Andrx Pharmaceuticals L.L.C. Pharmaceutical formulation for acid-labile compounds
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1234058A (en) 1968-10-21 1971-06-03
US4045564A (en) 1974-02-18 1977-08-30 Ab Hassle Benzimidazole derivatives useful as gastric acid secretion inhibitors
SE416649B (en) 1974-05-16 1981-01-26 Haessle Ab PROCEDURE FOR THE PREPARATION OF SUBSTANCES WHICH PREVENT Gastric acid secretion
IN148930B (en) 1977-09-19 1981-07-25 Hoffmann La Roche
SE7804231L (en) 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
CA1129417A (en) 1978-04-14 1982-08-10 Aktiebolaget Hassle Gastric acid secretion inhibiting substituted 2-(2- benzimidazolyl)-pyridines, their preparation, pharmaceutical preparations containing same, and method for inhibiting gastricacid secretion
FR2471186A1 (en) 1979-12-10 1981-06-19 Roussel Uclaf NEW COLIC DELITESCENCE TABLETS AND THEIR PREPARATION PROCESS
US4359465A (en) 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
SE8204879D0 (en) 1982-08-26 1982-08-26 Haessle Ab NOVEL CHEMICAL INTERMEDIATES
SE8301182D0 (en) 1983-03-04 1983-03-04 Haessle Ab NOVEL COMPOUNDS
US4716041A (en) 1984-02-10 1987-12-29 A/S Alfred Benzon Diffusion coated multiple-units dosage form
SE8403179D0 (en) 1984-06-13 1984-06-13 Haessle Ab NEW COMPOUNDS
IL76839A (en) 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CA1338377C (en) 1986-02-13 1996-06-11 Tadashi Makino Stabilized pharmaceutical composition and its production
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
SE457326B (en) 1986-02-14 1988-12-19 Lejus Medical Ab PROCEDURES FOR PREPARING A QUICK SUBSTANTIAL CANDLES CONTAINING BLA MICROCRISTALLIN CELLULOSA
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5330982A (en) 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
DK171989B1 (en) 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Process for the preparation of 2- (2-pyridylmethylsulfinyl) benzimidazoles
GB8809421D0 (en) 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
WO1990000054A1 (en) 1988-06-30 1990-01-11 The Upjohn Company Transdermal antisecretory agents for gastrointestinal disease
JP2694361B2 (en) 1989-02-09 1997-12-24 アストラ アクチエボラグ Antibacterial agent
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
IE66933B1 (en) 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
KR920008161B1 (en) * 1990-02-19 1992-09-24 한미약품공업주식회사 Process for preparing omeprazole oral preparation
SE9002043D0 (en) 1990-06-07 1990-06-07 Astra Ab IMPROVED METHOD FOR SYNTHESIS
KR930006431B1 (en) 1990-10-11 1993-07-16 재단법인 한국화학연구소 Microcapsulation of drugs
US5352688A (en) 1991-02-14 1994-10-04 The Mount Sinai School Of Medicine Of The City University Of New York Methods for the treatment of bradyphrenia in parkinson's disease
US5244670A (en) 1991-04-04 1993-09-14 The Procter & Gamble Company Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
DK0519144T3 (en) 1991-06-21 1998-03-23 Ilsan Ilac Ve Hammaddeleri San New galenic process for omeprazole containing pellets
US5178867A (en) 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
EP0661966B1 (en) 1991-12-17 2000-07-19 Biovail Technologies Ltd. Ulcer prevention and treatment composition and method
TW224049B (en) 1991-12-31 1994-05-21 Sunkyong Ind Ltd
TW276996B (en) 1992-04-24 1996-06-01 Astra Ab
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
FR2692146B1 (en) 1992-06-16 1995-06-02 Ethypharm Sa Stable compositions of gastro-protected omeprazole microgranules and process for obtaining them.
RU95105442A (en) 1992-07-08 1997-02-20 Монсанто Компани (US) Method of stomach ulcer treatment in pigs, agent for stomach ulcer treatment in pigs
WO1994002141A1 (en) 1992-07-28 1994-02-03 Astra Aktiebolag Injection and injection kit containing omeprazole and its analogs
MX9304638A (en) 1992-07-31 1994-05-31 Neose Pharm Inc COMPOSITION TO TREAT AND INHIBIT GASTRIC AND DUODENAL ULCERS.
SE9301830D0 (en) 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
SE9302395D0 (en) 1993-07-09 1993-07-09 Ab Astra NEW PHARMACEUTICAL FORMULATION
SE9302396D0 (en) 1993-07-09 1993-07-09 Ab Astra A NOVEL COMPOUND FORM
AU683092B2 (en) 1993-10-12 1997-10-30 Mitsubishi-Tokyo Pharmaceuticals, Inc. Tablet containing enteric granules
US5374730A (en) 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
EP1078628B1 (en) 1994-07-08 2008-11-19 AstraZeneca AB Multiple unit tableted dosage form
CA2193681A1 (en) 1994-07-08 1996-01-25 Astra Aktiebolag New oral pharmaceutical formulation containing magnesium salt of omeprazole
SE9402431D0 (en) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
SE504459C2 (en) 1994-07-15 1997-02-17 Astra Ab Process for the preparation of substituted sulfoxides
SE9500422D0 (en) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9600070D0 (en) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
TR199902233T2 (en) * 1997-03-13 1999-12-21 Hexal Ag Stabilization of acid-sensitive benzimidazoles by amino acid/cyclodextrin combinations.
ES2137862B1 (en) 1997-07-31 2000-09-16 Intexim S A ORAL PHARMACEUTICAL PREPARATION INCLUDING A COMPOUND OF ANTI-ULCER ACTIVITY AND PROCEDURE FOR ITS OBTAINING.
US6296876B1 (en) * 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786505A (en) * 1986-04-30 1988-11-22 Aktiebolaget Hassle Pharmaceutical preparation for oral use
US5219870A (en) * 1990-02-27 1993-06-15 Kwang Sik Kim Omeprazole compositions designed for administration in rectum
US6013281A (en) * 1995-02-09 2000-01-11 Astra Aktiebolag Method of making a pharmaceutical dosage form comprising a proton pump inhibitor
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6602522B1 (en) * 1997-11-14 2003-08-05 Andrx Pharmaceuticals L.L.C. Pharmaceutical formulation for acid-labile compounds
US6780435B2 (en) * 1997-11-14 2004-08-24 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196485A1 (en) * 1999-06-22 2007-08-23 Dexcel Ltd. Stable benzimidazole formulation
US9023391B2 (en) 1999-06-22 2015-05-05 Dexcel Ltd. Stable benzimidazole formulation
US20070243243A1 (en) * 2006-04-04 2007-10-18 Cogentus Pharmaceuticals, Inc Oral dosage forms including an antiplatelet agent and an acid inhibitor
US20090214602A1 (en) * 2006-04-04 2009-08-27 Mark Goldsmith Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
US9504678B2 (en) * 2006-04-04 2016-11-29 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an acid inhibitor
US9532945B2 (en) 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
US20110038933A1 (en) * 2008-05-06 2011-02-17 Dexcell Ltd. Stable benzimidazole formulation
US10835488B2 (en) 2016-06-16 2020-11-17 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10137111B2 (en) 2016-08-11 2018-11-27 Adamis Pharmaceuticals Corporation Drug compositions comprising an anti-parasitic and proton pump inhibitor
US11045450B2 (en) 2016-08-11 2021-06-29 Adamis Pharmaceuticals Corporation Drug compositions
US11564910B2 (en) 2017-12-08 2023-01-31 Adamis Pharmaceuticals Corporation Drug compositions

Also Published As

Publication number Publication date
US6733778B1 (en) 2004-05-11
US6855336B2 (en) 2005-02-15
US20040131684A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AU767289B2 (en) Omeprazole formulation
US6733778B1 (en) Omeprazole formulation
US6515010B1 (en) Carvedilol methanesulfonate
US7029701B2 (en) Composition for the treatment and prevention of ischemic events
JP3699122B2 (en) New oral pharmaceutical use form
US20030113376A1 (en) Omeprazole formulation
US20040028735A1 (en) Pharmaceutical formulation
US20090175935A1 (en) Pharmaceutical compositions of duloxetine
RS77904A (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
US6602522B1 (en) Pharmaceutical formulation for acid-labile compounds
AU2012357795B2 (en) New combination
WO2011140446A2 (en) Pharmaceutical formulations
US20130216617A1 (en) Pharmaceutical compositions of (r)-lansoprazole
US20030129236A1 (en) Multiple pulse extended release formulations of clindamycin
HUP0004345A2 (en) A new oral medicinal product containing carvedilol
AU2002314306B8 (en) Pharmaceutical composition containing stool softener such as polaxamer and enteric coated particles of bisacodyl
EP2345408A2 (en) Acid labile drug formulations
EP1594479A1 (en) Stable oral benzimidazole compositions and processes for their preparation
US20100080846A1 (en) Dipyridamole and acetylsalicylic acid formulations and process for preparing same
US8658216B2 (en) Stable oral benzimidazole compositions and process of preparation thereof
US20090175934A1 (en) Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same
CA2547398A1 (en) Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating
CA2667039A1 (en) Multiple unit tablet compositions of benzimidazole compounds
NZ510231A (en) Omeprazole formulation comprising an alkaline core and an enteric coating
US20240269084A1 (en) Delayed release compositions of dimethyl fumarate

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION